XenoPort May Be Beneficiary of Biogen Patent Filings
March 20, 2013 at 09:11 AM EDT
Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB ) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT ). Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12,
